2024
Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract
Mao T, Kim J, Peña-Hernández M, Valle G, Moriyama M, Luyten S, Ott I, Gomez-Calvo M, Gehlhausen J, Baker E, Israelow B, Slade M, Sharma L, Liu W, Ryu C, Korde A, Lee C, Monteiro V, Lucas C, Dong H, Yang Y, Initiative Y, Gopinath S, Wilen C, Palm N, Dela Cruz C, Iwasaki A, Vogels C, Hahn A, Chen N, Breban M, Koch T, Chaguza C, Tikhonova I, Castaldi C, Mane S, De Kumar B, Ferguson D, Kerantzas N, Peaper D, Landry M, Schulz W, Grubaugh N. Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2319566121. PMID: 38648490, PMCID: PMC11067057, DOI: 10.1073/pnas.2319566121.Peer-Reviewed Original ResearchConceptsInterferon-stimulated genesRespiratory infectionsStrains of influenza A virusTreatment of respiratory viral infectionsRespiratory virus infectionsInfluenza A virusMouse model of COVID-19Respiratory viral infectionsNeomycin treatmentExpression of interferon-stimulated genesUpper respiratory infectionInterferon-stimulated gene expressionLower respiratory infectionsBroad spectrum of diseasesAdministration of neomycinRespiratory viral diseasesDisease to patientsUpper respiratory tractIntranasal deliveryCongenic miceIntranasal applicationNasal mucosaSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2A virus
2021
JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis
Walz L, Cohen AJ, Rebaza AP, Vanchieri J, Slade MD, Dela Cruz CS, Sharma L. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. BMC Infectious Diseases 2021, 21: 47. PMID: 33430799, PMCID: PMC7797881, DOI: 10.1186/s12879-020-05730-z.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19COVID-19 Drug TreatmentHumansInterferon Type IJanus Kinase InhibitorsSARS-CoV-2Treatment OutcomeConceptsCOVID-19 patientsType I interferonOdds of mortalityPositive clinical outcomesClinical outcomesI interferonICU admissionExcessive cytokine releaseType I interferon treatmentStandard treatment groupOdds of dischargeFavorable clinical outcomeNon-randomized trialsJanus kinase inhibitorSearch of MEDLINETerms of mortalityKinase inhibitor treatmentHospital dischargeCytokine releaseInterferon treatmentPotential antiviral candidatesNovel therapiesTreatment outcomesTreatment groupsAntiviral candidates
2020
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
Xiao X, Wang C, Chang D, Wang Y, Dong X, Jiao T, Zhao Z, Ren L, Dela Cruz CS, Sharma L, Lei X, Wang J. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. Frontiers In Immunology 2020, 11: 586572. PMID: 33324406, PMCID: PMC7723961, DOI: 10.3389/fimmu.2020.586572.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Therapeutic agentsAnti-coronaviral activitySARS-CoV-2 drugsWide therapeutic windowCOVID-19 infectionNovel therapeutic agentsEffective compoundsTherapeutic optionsReplication of coronavirusesSafe drugSevere diseaseTherapeutic windowHuman coronavirusesTherapeutic candidateUS FDAArbidol hydrochlorideIdentification of PotentTwo-step screenMillions of peopleSafety indexDrugsCOVID-19 pandemicFDACoronavirusReply to Suri et al.: COVID-19 Real-Time RT-PCR: Does Positivity on Follow-up RT-PCR Always Imply Infectivity?
Chang D, Mo G, Yuan X, Tao Y, Peng X, Wang F, Xie L, Sharma L, Dela Cruz CS, Qin E. Reply to Suri et al.: COVID-19 Real-Time RT-PCR: Does Positivity on Follow-up RT-PCR Always Imply Infectivity? American Journal Of Respiratory And Critical Care Medicine 2020, 202: 148-148. PMID: 32401535, PMCID: PMC7328309, DOI: 10.1164/rccm.202004-1458le.Commentaries, Editorials and Letters